{"id":417893,"date":"2021-01-20T10:03:17","date_gmt":"2021-01-20T15:03:17","guid":{"rendered":"http:\/\/www.marketnewsdesk.com\/?p=417893"},"modified":"2021-01-20T10:03:17","modified_gmt":"2021-01-20T15:03:17","slug":"precipio-signs-hemescreen-deals-with-two-leading-oncology-groups","status":"publish","type":"post","link":"https:\/\/www.marketnewsdesk.com\/index.php\/precipio-signs-hemescreen-deals-with-two-leading-oncology-groups\/","title":{"rendered":"Precipio Signs HemeScreen\u2122 Deals with Two Leading Oncology Groups"},"content":{"rendered":"

\nPartnership with ION Solutions expected to accelerate sales
\n<\/h2>\n
\n

NEW HAVEN, Conn., Jan. 20, 2021 (GLOBE NEWSWIRE) — Specialty cancer diagnostics company\u00a0Precipio, Inc.<\/u><\/a>\u00a0(NASDAQ: PRPO)<\/u><\/a> has signed agreements with two of the largest oncology practices in the US, West Cancer Center<\/u><\/a> of Memphis, TN; and New York Cancer & Blood Specialists<\/u><\/a> of New York. During the coming weeks, both practices will be bringing Precipio\u2019s HemeScreen technology in-house. The implementation of HemeScreen will enable these practices to significantly improve turnaround time for important molecular tests for diseases such as MPN (Myeloproliferative Neoplasms), CLL (Chronic Lymphocytic Leukemia) and AML (Acute Myeloid Leukemia), delivering better care to their cancer patients.<\/p>\n

Following the recent publication<\/u><\/a> introducing HemeScreen to physician office laboratories (POLs) in ION\u2019s Oncologists Magazine<\/u><\/a>, the partnership with ION has the potential to continue to open doors to hundreds of independent community oncology practices nationwide, with a joint effort of both companies\u2019 sales teams to introduce this patient-centric technology to those groups.<\/p>\n

The onboarding of these two customers will have a material impact to Precipio, and has the potential to generate seven-figure revenue to Precipio. As Precipio\u2019s R&D team continues to expand its panels and its HemeScreen offering to new diseases, the company\u2019s growing installed customer base will benefit from broadened testing opportunities, increasing revenue to the oncology practice. These ongoing developments will also have the potential of delivering increased market share and revenue to Precipio from expanded reagent sales.<\/p>\n

\u201cAs a patient-centric practice, we are constantly seeking innovative technologies to improve the way we care for our patients\u201d, said Dr. Vacirca, CEO of New York Cancer & Blood Specialists. \u201cHemeScreen will help us identify the patient\u2019s molecular profile faster, so that we can deliver the best, most accurate and rapid care to our patients.\u201d<\/p>\n

\u201cThe trust that these prominent practices have placed in Precipio is a testament to the value, both clinical and financial, of HemeScreen to the market; we are excited to continue and rapidly expand the market penetration of HemeScreen in the POL market\u201d, said Ilan Danieli, Precipio\u2019s CEO. \u201cConsistent with our mission, we are delighted to play a role in continuing to help the diagnostic community provide better care and reduced diagnostic errors for their patients\u201d.<\/p>\n

\n About Precipio<\/strong>\n <\/p>\n

Precipio has built a platform designed to eradicate the problem of misdiagnosis by harnessing the intellect, expertise and technology developed within academic institutions and delivering quality diagnostic information to physicians and their patients worldwide. Through its collaborations with world-class academic institutions specializing in cancer research, diagnostics and treatment such as the Yale School of Medicine, Harvard\u2019s Dana-Farber Cancer Institute, and the University of Pennsylvania, Precipio offers a new standard of diagnostic accuracy enabling the highest level of patient care. For more information, please visit www.precipiodx.com<\/u><\/a>.<\/p>\n

\n About HemeScreen\u2122 Reagent Rental (HSRR) Program<\/strong>\n <\/p>\n

Precipio\u2019s HemeScreen Reagent Rental Program for POLs applies its patent-pending HemeScreen\u2122 technology beyond the laboratory and into the point of care setting, in the oncologist\u2019s office. A tried-and-true structure that is prevalent in the diagnostic world, the HemeScreen Reagent Rental (HSRR) program enables office-based physicians to place Real-Time PCR (RT-PCR) testing equipment with no capital outlay and generate profitable revenue from day one.<\/p>\n

Through this program, the physician practice will have the ability to run the diagnostic tests in-house instead of sending out to reference laboratories, obtaining faster results and providing patients with better care. All panels and genes are reimbursed by Medicare and insurance companies. Customers make one monthly payment to purchase HemeScreen reagents, which will subsidize the cost of the PCR equipment and all necessary support, creating a profitable business model for the POLs.<\/p>\n

For more information please visit our website at http:\/\/www.precipiodx.com\/hemescreen.html<\/u><\/a>.<\/p>\n

\n Forward-Looking Statements<\/strong>\n <\/p>\n

This press release contains \u201cforward-looking statements\u201d within the meaning of Section 27A of the Securities Act of 1933, as amended, and Section 21E of the Securities Exchange Act of 1934, as amended, including, among others, statements related to the expected or potential impact of the novel coronavirus (COVID-19) pandemic, and the related responses of the government, consumers, and the company, on our business, financial condition and results of operations, and any such forward-looking statements, whether concerning the COVID-19 pandemic or otherwise, involve risks, assumptions and uncertainties. Except for historical information, statements about future volumes, sales, growth, costs, cost savings, margins, earnings, earnings per share, diluted earnings per share, cash flows, plans, objectives, expectations, growth or profitability are forward-looking statements based on management\u2019s estimates, beliefs, assumptions and projections. Words such as \u201ccould,\u201d \u201cmay,\u201d \u201cexpects,\u201d \u201canticipates,\u201d \u201cwill,\u201d \u201ctargets,\u201d \u201cgoals,\u201d \u201cprojects,\u201d \u201cintends,\u201d \u201cplans,\u201d \u201cbelieves,\u201d \u201cseeks,\u201d \u201cestimates,\u201d \u201cpredicts,\u201d and variations on such words, and similar expressions that reflect our current views with respect to future events and operational, economic and financial performance, are intended to identify such forward-looking statements. These forward-looking statements are only predictions, subject to risks and uncertainties, and actual results could differ materially from those discussed. Important factors that could affect performance and cause results to differ materially from management\u2019s expectations, or could affect the company\u2019s ability to achieve its strategic goals, include the uncertainties relating to the impact of COVID-19 on the company\u2019s business, operations and employees and the other factors that are described in the sections entitled \u201cRisk Factors\u201d and \u201cManagement\u2019s Discussion and Analysis\u201d in the company’s Annual Report on Form 10-K for the fiscal year ended December 31, 2019, as updated from time to time in the company\u2019s Securities and Exchange Commission filings.<\/p>\n

The company\u2019s forward-looking statements in this press release are based on management\u2019s current views, beliefs, assumptions and expectations regarding future events and speak only as of the date of this release. The company undertakes no obligation to publicly update or revise any forward-looking statements, whether as a result of new information, future events or otherwise, except as required by the federal securities laws.\u00a0<\/p>\n


\n
\n \n <\/div>\n

\n
Inquiries:\r\n\r\ninvestors@precipiodx.com\r\n\r\n+1-203-787-7888 Ext. 523<\/pre>\n<\/p><\/div>\n","protected":false},"excerpt":{"rendered":"
Partnership with ION Solutions expected to accelerate sales NEW HAVEN, Conn., Jan. 20, 2021 (GLOBE NEWSWIRE) — Specialty cancer diagnostics company\u00a0Precipio, Inc.\u00a0(NASDAQ: PRPO) has signed agreements with two of the largest oncology practices in the US, West Cancer Center of Memphis, TN; and New York Cancer & Blood Specialists of New York. During the coming weeks, both practices will be bringing Precipio\u2019s HemeScreen technology in-house. The implementation of HemeScreen will enable these practices to significantly improve turnaround time for important molecular tests for diseases such as MPN (Myeloproliferative Neoplasms), CLL (Chronic Lymphocytic Leukemia) and AML (Acute Myeloid Leukemia), delivering better care to their cancer patients. Following the recent publication introducing HemeScreen to physician office laboratories (POLs) in ION\u2019s Oncologists Magazine, … <\/p>\n
Continue reading “Precipio Signs HemeScreen\u2122 Deals with Two Leading Oncology Groups”<\/span><\/a><\/p>\n","protected":false},"author":2,"featured_media":0,"comment_status":"closed","ping_status":"closed","sticky":false,"template":"","format":"standard","meta":{"footnotes":""},"categories":[],"tags":[],"class_list":["post-417893","post","type-post","status-publish","format-standard","hentry"],"yoast_head":"\nPrecipio Signs HemeScreen\u2122 Deals with Two Leading Oncology Groups - Market Newsdesk<\/title>\n<meta name=\"robots\" content=\"index, follow, max-snippet:-1, max-image-preview:large, max-video-preview:-1\" \/>\n<link rel=\"canonical\" href=\"https:\/\/www.marketnewsdesk.com\/index.php\/precipio-signs-hemescreen-deals-with-two-leading-oncology-groups\/\" \/>\n<meta property=\"og:locale\" content=\"en_US\" \/>\n<meta property=\"og:type\" content=\"article\" \/>\n<meta property=\"og:title\" content=\"Precipio Signs HemeScreen\u2122 Deals with Two Leading Oncology Groups - Market Newsdesk\" \/>\n<meta property=\"og:description\" content=\"Partnership with ION Solutions expected to accelerate sales NEW HAVEN, Conn., Jan. 20, 2021 (GLOBE NEWSWIRE) — Specialty cancer diagnostics company\u00a0Precipio, Inc.\u00a0(NASDAQ: PRPO) has signed agreements with two of the largest oncology practices in the US, West Cancer Center of Memphis, TN; and New York Cancer & Blood Specialists of New York. During the coming weeks, both practices will be bringing Precipio\u2019s HemeScreen technology in-house. The implementation of HemeScreen will enable these practices to significantly improve turnaround time for important molecular tests for diseases such as MPN (Myeloproliferative Neoplasms), CLL (Chronic Lymphocytic Leukemia) and AML (Acute Myeloid Leukemia), delivering better care to their cancer patients. Following the recent publication introducing HemeScreen to physician office laboratories (POLs) in ION\u2019s Oncologists Magazine, … Continue reading "Precipio Signs HemeScreen\u2122 Deals with Two Leading Oncology Groups"\" \/>\n<meta property=\"og:url\" content=\"https:\/\/www.marketnewsdesk.com\/index.php\/precipio-signs-hemescreen-deals-with-two-leading-oncology-groups\/\" \/>\n<meta property=\"og:site_name\" content=\"Market Newsdesk\" \/>\n<meta property=\"article:published_time\" content=\"2021-01-20T15:03:17+00:00\" \/>\n<meta property=\"og:image\" content=\"https:\/\/www.globenewswire.com\/newsroom\/ti?nf=ODEzODE5OCMzOTM0MDU2IzIwOTYwMTU=\" \/>\n<meta name=\"author\" content=\"Newsdesk\" \/>\n<meta name=\"twitter:card\" content=\"summary_large_image\" \/>\n<meta name=\"twitter:label1\" content=\"Written by\" \/>\n\t<meta name=\"twitter:data1\" content=\"Newsdesk\" \/>\n\t<meta name=\"twitter:label2\" content=\"Est. reading time\" \/>\n\t<meta name=\"twitter:data2\" content=\"5 minutes\" \/>\n<script type=\"application\/ld+json\" class=\"yoast-schema-graph\">{\"@context\":\"https:\\\/\\\/schema.org\",\"@graph\":[{\"@type\":\"Article\",\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/precipio-signs-hemescreen-deals-with-two-leading-oncology-groups\\\/#article\",\"isPartOf\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/precipio-signs-hemescreen-deals-with-two-leading-oncology-groups\\\/\"},\"author\":{\"name\":\"Newsdesk\",\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/#\\\/schema\\\/person\\\/482f27a394d4fda80ecb5499e519d979\"},\"headline\":\"Precipio Signs HemeScreen\u2122 Deals with Two Leading Oncology Groups\",\"datePublished\":\"2021-01-20T15:03:17+00:00\",\"mainEntityOfPage\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/precipio-signs-hemescreen-deals-with-two-leading-oncology-groups\\\/\"},\"wordCount\":984,\"image\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/precipio-signs-hemescreen-deals-with-two-leading-oncology-groups\\\/#primaryimage\"},\"thumbnailUrl\":\"https:\\\/\\\/www.globenewswire.com\\\/newsroom\\\/ti?nf=ODEzODE5OCMzOTM0MDU2IzIwOTYwMTU=\",\"inLanguage\":\"en-US\"},{\"@type\":\"WebPage\",\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/precipio-signs-hemescreen-deals-with-two-leading-oncology-groups\\\/\",\"url\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/precipio-signs-hemescreen-deals-with-two-leading-oncology-groups\\\/\",\"name\":\"Precipio Signs HemeScreen\u2122 Deals with Two Leading Oncology Groups - Market Newsdesk\",\"isPartOf\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/#website\"},\"primaryImageOfPage\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/precipio-signs-hemescreen-deals-with-two-leading-oncology-groups\\\/#primaryimage\"},\"image\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/precipio-signs-hemescreen-deals-with-two-leading-oncology-groups\\\/#primaryimage\"},\"thumbnailUrl\":\"https:\\\/\\\/www.globenewswire.com\\\/newsroom\\\/ti?nf=ODEzODE5OCMzOTM0MDU2IzIwOTYwMTU=\",\"datePublished\":\"2021-01-20T15:03:17+00:00\",\"author\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/#\\\/schema\\\/person\\\/482f27a394d4fda80ecb5499e519d979\"},\"breadcrumb\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/precipio-signs-hemescreen-deals-with-two-leading-oncology-groups\\\/#breadcrumb\"},\"inLanguage\":\"en-US\",\"potentialAction\":[{\"@type\":\"ReadAction\",\"target\":[\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/precipio-signs-hemescreen-deals-with-two-leading-oncology-groups\\\/\"]}]},{\"@type\":\"ImageObject\",\"inLanguage\":\"en-US\",\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/precipio-signs-hemescreen-deals-with-two-leading-oncology-groups\\\/#primaryimage\",\"url\":\"https:\\\/\\\/www.globenewswire.com\\\/newsroom\\\/ti?nf=ODEzODE5OCMzOTM0MDU2IzIwOTYwMTU=\",\"contentUrl\":\"https:\\\/\\\/www.globenewswire.com\\\/newsroom\\\/ti?nf=ODEzODE5OCMzOTM0MDU2IzIwOTYwMTU=\"},{\"@type\":\"BreadcrumbList\",\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/precipio-signs-hemescreen-deals-with-two-leading-oncology-groups\\\/#breadcrumb\",\"itemListElement\":[{\"@type\":\"ListItem\",\"position\":1,\"name\":\"Home\",\"item\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/\"},{\"@type\":\"ListItem\",\"position\":2,\"name\":\"Precipio Signs HemeScreen\u2122 Deals with Two Leading Oncology Groups\"}]},{\"@type\":\"WebSite\",\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/#website\",\"url\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/\",\"name\":\"Market Newsdesk\",\"description\":\"Latest Business News in Real Time\",\"potentialAction\":[{\"@type\":\"SearchAction\",\"target\":{\"@type\":\"EntryPoint\",\"urlTemplate\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/?s={search_term_string}\"},\"query-input\":{\"@type\":\"PropertyValueSpecification\",\"valueRequired\":true,\"valueName\":\"search_term_string\"}}],\"inLanguage\":\"en-US\"},{\"@type\":\"Person\",\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/#\\\/schema\\\/person\\\/482f27a394d4fda80ecb5499e519d979\",\"name\":\"Newsdesk\",\"image\":{\"@type\":\"ImageObject\",\"inLanguage\":\"en-US\",\"@id\":\"https:\\\/\\\/secure.gravatar.com\\\/avatar\\\/a0d0bd5b0f0ca12a265a459b13169dac35f33776d8501eda5e68844a366f2f46?s=96&d=mm&r=g\",\"url\":\"https:\\\/\\\/secure.gravatar.com\\\/avatar\\\/a0d0bd5b0f0ca12a265a459b13169dac35f33776d8501eda5e68844a366f2f46?s=96&d=mm&r=g\",\"contentUrl\":\"https:\\\/\\\/secure.gravatar.com\\\/avatar\\\/a0d0bd5b0f0ca12a265a459b13169dac35f33776d8501eda5e68844a366f2f46?s=96&d=mm&r=g\",\"caption\":\"Newsdesk\"},\"url\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/author\\\/newsdesk\\\/\"}]}<\/script>\n<!-- \/ Yoast SEO plugin. -->","yoast_head_json":{"title":"Precipio Signs HemeScreen\u2122 Deals with Two Leading Oncology Groups - Market Newsdesk","robots":{"index":"index","follow":"follow","max-snippet":"max-snippet:-1","max-image-preview":"max-image-preview:large","max-video-preview":"max-video-preview:-1"},"canonical":"https:\/\/www.marketnewsdesk.com\/index.php\/precipio-signs-hemescreen-deals-with-two-leading-oncology-groups\/","og_locale":"en_US","og_type":"article","og_title":"Precipio Signs HemeScreen\u2122 Deals with Two Leading Oncology Groups - Market Newsdesk","og_description":"Partnership with ION Solutions expected to accelerate sales NEW HAVEN, Conn., Jan. 20, 2021 (GLOBE NEWSWIRE) — Specialty cancer diagnostics company\u00a0Precipio, Inc.\u00a0(NASDAQ: PRPO) has signed agreements with two of the largest oncology practices in the US, West Cancer Center of Memphis, TN; and New York Cancer & Blood Specialists of New York. During the coming weeks, both practices will be bringing Precipio\u2019s HemeScreen technology in-house. The implementation of HemeScreen will enable these practices to significantly improve turnaround time for important molecular tests for diseases such as MPN (Myeloproliferative Neoplasms), CLL (Chronic Lymphocytic Leukemia) and AML (Acute Myeloid Leukemia), delivering better care to their cancer patients. Following the recent publication introducing HemeScreen to physician office laboratories (POLs) in ION\u2019s Oncologists Magazine, … Continue reading \"Precipio Signs HemeScreen\u2122 Deals with Two Leading Oncology Groups\"","og_url":"https:\/\/www.marketnewsdesk.com\/index.php\/precipio-signs-hemescreen-deals-with-two-leading-oncology-groups\/","og_site_name":"Market Newsdesk","article_published_time":"2021-01-20T15:03:17+00:00","og_image":[{"url":"https:\/\/www.globenewswire.com\/newsroom\/ti?nf=ODEzODE5OCMzOTM0MDU2IzIwOTYwMTU=","type":"","width":"","height":""}],"author":"Newsdesk","twitter_card":"summary_large_image","twitter_misc":{"Written by":"Newsdesk","Est. reading time":"5 minutes"},"schema":{"@context":"https:\/\/schema.org","@graph":[{"@type":"Article","@id":"https:\/\/www.marketnewsdesk.com\/index.php\/precipio-signs-hemescreen-deals-with-two-leading-oncology-groups\/#article","isPartOf":{"@id":"https:\/\/www.marketnewsdesk.com\/index.php\/precipio-signs-hemescreen-deals-with-two-leading-oncology-groups\/"},"author":{"name":"Newsdesk","@id":"https:\/\/www.marketnewsdesk.com\/#\/schema\/person\/482f27a394d4fda80ecb5499e519d979"},"headline":"Precipio Signs HemeScreen\u2122 Deals with Two Leading Oncology Groups","datePublished":"2021-01-20T15:03:17+00:00","mainEntityOfPage":{"@id":"https:\/\/www.marketnewsdesk.com\/index.php\/precipio-signs-hemescreen-deals-with-two-leading-oncology-groups\/"},"wordCount":984,"image":{"@id":"https:\/\/www.marketnewsdesk.com\/index.php\/precipio-signs-hemescreen-deals-with-two-leading-oncology-groups\/#primaryimage"},"thumbnailUrl":"https:\/\/www.globenewswire.com\/newsroom\/ti?nf=ODEzODE5OCMzOTM0MDU2IzIwOTYwMTU=","inLanguage":"en-US"},{"@type":"WebPage","@id":"https:\/\/www.marketnewsdesk.com\/index.php\/precipio-signs-hemescreen-deals-with-two-leading-oncology-groups\/","url":"https:\/\/www.marketnewsdesk.com\/index.php\/precipio-signs-hemescreen-deals-with-two-leading-oncology-groups\/","name":"Precipio Signs HemeScreen\u2122 Deals with Two Leading Oncology Groups - Market Newsdesk","isPartOf":{"@id":"https:\/\/www.marketnewsdesk.com\/#website"},"primaryImageOfPage":{"@id":"https:\/\/www.marketnewsdesk.com\/index.php\/precipio-signs-hemescreen-deals-with-two-leading-oncology-groups\/#primaryimage"},"image":{"@id":"https:\/\/www.marketnewsdesk.com\/index.php\/precipio-signs-hemescreen-deals-with-two-leading-oncology-groups\/#primaryimage"},"thumbnailUrl":"https:\/\/www.globenewswire.com\/newsroom\/ti?nf=ODEzODE5OCMzOTM0MDU2IzIwOTYwMTU=","datePublished":"2021-01-20T15:03:17+00:00","author":{"@id":"https:\/\/www.marketnewsdesk.com\/#\/schema\/person\/482f27a394d4fda80ecb5499e519d979"},"breadcrumb":{"@id":"https:\/\/www.marketnewsdesk.com\/index.php\/precipio-signs-hemescreen-deals-with-two-leading-oncology-groups\/#breadcrumb"},"inLanguage":"en-US","potentialAction":[{"@type":"ReadAction","target":["https:\/\/www.marketnewsdesk.com\/index.php\/precipio-signs-hemescreen-deals-with-two-leading-oncology-groups\/"]}]},{"@type":"ImageObject","inLanguage":"en-US","@id":"https:\/\/www.marketnewsdesk.com\/index.php\/precipio-signs-hemescreen-deals-with-two-leading-oncology-groups\/#primaryimage","url":"https:\/\/www.globenewswire.com\/newsroom\/ti?nf=ODEzODE5OCMzOTM0MDU2IzIwOTYwMTU=","contentUrl":"https:\/\/www.globenewswire.com\/newsroom\/ti?nf=ODEzODE5OCMzOTM0MDU2IzIwOTYwMTU="},{"@type":"BreadcrumbList","@id":"https:\/\/www.marketnewsdesk.com\/index.php\/precipio-signs-hemescreen-deals-with-two-leading-oncology-groups\/#breadcrumb","itemListElement":[{"@type":"ListItem","position":1,"name":"Home","item":"https:\/\/www.marketnewsdesk.com\/"},{"@type":"ListItem","position":2,"name":"Precipio Signs HemeScreen\u2122 Deals with Two Leading Oncology Groups"}]},{"@type":"WebSite","@id":"https:\/\/www.marketnewsdesk.com\/#website","url":"https:\/\/www.marketnewsdesk.com\/","name":"Market Newsdesk","description":"Latest Business News in Real Time","potentialAction":[{"@type":"SearchAction","target":{"@type":"EntryPoint","urlTemplate":"https:\/\/www.marketnewsdesk.com\/?s={search_term_string}"},"query-input":{"@type":"PropertyValueSpecification","valueRequired":true,"valueName":"search_term_string"}}],"inLanguage":"en-US"},{"@type":"Person","@id":"https:\/\/www.marketnewsdesk.com\/#\/schema\/person\/482f27a394d4fda80ecb5499e519d979","name":"Newsdesk","image":{"@type":"ImageObject","inLanguage":"en-US","@id":"https:\/\/secure.gravatar.com\/avatar\/a0d0bd5b0f0ca12a265a459b13169dac35f33776d8501eda5e68844a366f2f46?s=96&d=mm&r=g","url":"https:\/\/secure.gravatar.com\/avatar\/a0d0bd5b0f0ca12a265a459b13169dac35f33776d8501eda5e68844a366f2f46?s=96&d=mm&r=g","contentUrl":"https:\/\/secure.gravatar.com\/avatar\/a0d0bd5b0f0ca12a265a459b13169dac35f33776d8501eda5e68844a366f2f46?s=96&d=mm&r=g","caption":"Newsdesk"},"url":"https:\/\/www.marketnewsdesk.com\/index.php\/author\/newsdesk\/"}]}},"_links":{"self":[{"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/posts\/417893","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/posts"}],"about":[{"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/types\/post"}],"author":[{"embeddable":true,"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/users\/2"}],"replies":[{"embeddable":true,"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/comments?post=417893"}],"version-history":[{"count":0,"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/posts\/417893\/revisions"}],"wp:attachment":[{"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/media?parent=417893"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/categories?post=417893"},{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/tags?post=417893"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}